Published in Clin Vaccine Immunol on July 03, 2012
Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection. Mucosal Immunol (2016) 0.81
Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae. Clin Vaccine Immunol (2014) 0.76
A combination of recombinant BCG expressing pneumococcal proteins induces cellular and humoral immune responses and protects against pneumococcal colonization and sepsis. Clin Vaccine Immunol (2017) 0.75
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet (2009) 15.31
Rapid pneumococcal evolution in response to clinical interventions. Science (2011) 9.09
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis (2010) 8.37
Serotype replacement in disease after pneumococcal vaccination. Lancet (2011) 7.14
Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog (2008) 4.05
Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods (1990) 3.48
TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol (2006) 3.44
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A (2005) 3.30
Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest (2009) 3.16
Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis (2000) 2.55
Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun (2006) 2.20
Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine (2000) 2.07
Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun (2004) 1.91
Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun (2008) 1.87
Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect Immun (2003) 1.83
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine (2000) 1.82
Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun (2006) 1.80
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun (2001) 1.74
Construction of plasmid vectors for the detection of streptococcal promoters. Gene (1986) 1.69
Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection. Infect Immun (2002) 1.59
Evaluation of lung injury in rats and mice. Am J Physiol Lung Cell Mol Physiol (2004) 1.54
PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun (2004) 1.53
Nucleotide sequence determination and genetic analysis of the Bacteroides plasmid, pBI143. Plasmid (1995) 1.48
Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun (2007) 1.45
Serotype replacement in perspective. Vaccine (2009) 1.37
The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine (2009) 1.27
Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS One (2009) 1.25
Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun (2004) 1.18
Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol (2009) 1.18
CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in mice. J Immunol (2010) 1.17
Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J Med Microbiol (2008) 1.14
Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect (2009) 1.10
Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc Natl Acad Sci U S A (2012) 1.09
PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun (2009) 1.09
Multiple mechanisms of immune suppression by B lymphocytes. Mol Med (2012) 1.08
Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation. PLoS One (2011) 1.06
Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol (2010) 1.06
Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect (2006) 1.00
Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol (2010) 0.99
Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One (2010) 0.98
Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice. Infect Immun (2007) 0.96
Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes Infect (2008) 0.94
Survey of nonsusceptible nasopharyngeal Streptococcus pneumoniae isolates in children attending day-care centers in Brazil. Pediatr Infect Dis J (2010) 0.94
A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice. Infect Immun (2012) 0.94
Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol (2008) 0.93
Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine (2000) 0.91
Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice. Vaccine (2009) 0.89
Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains. Microb Pathog (2009) 0.88
Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol (2003) 0.87
Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Pediatr Infect Dis J (2009) 0.86
Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microb Pathog (2010) 0.86
Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice. Infect Immun (2011) 0.85
Immune response and protection against influenza A infection in mice immunised with subunit influenza A vaccine in combination with whole cell or acellular DTP vaccine. Vaccine (1995) 0.83
Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine (2000) 0.83
Induction of IL-2 and IFN-gamma in BALB/c mice immunised with subunit influenza A vaccine in combination with whole cell or acellular DTP vaccine. J Med Microbiol (1997) 0.82
Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide. Microb Pathog (2009) 0.82
Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nat Genet (2003) 2.66
Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med (2013) 1.84
The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease. Immunobiology (2009) 1.37
Whole-genome analysis of Leptospira interrogans to identify potential vaccine candidates against leptospirosis. FEMS Microbiol Lett (2005) 1.34
Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage. PLoS Pathog (2012) 1.18
Leptospiral TlyC is an extracellular matrix-binding protein and does not present hemolysin activity. FEBS Lett (2009) 1.16
Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J Med Microbiol (2008) 1.14
Experimental human pneumococcal carriage. J Vis Exp (2013) 1.09
Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol (2010) 1.06
Lachesis muta (Viperidae) cDNAs reveal diverging pit viper molecules and scaffolds typical of cobra (Elapidae) venoms: implications for snake toxin repertoire evolution. Genetics (2006) 1.04
Transcriptome analysis of Loxosceles laeta (Araneae, Sicariidae) spider venomous gland using expressed sequence tags. BMC Genomics (2008) 1.03
Overexpression of a synthetic gene encoding human alpha interferon in Escherichia coli. Protein Expr Purif (2004) 1.01
T regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice. PLoS Pathog (2012) 1.01
Lactic acid bacteria in the prevention of pneumococcal respiratory infection: future opportunities and challenges. Int Immunopharmacol (2011) 1.01
Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung. PLoS Pathog (2013) 1.01
Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine (2009) 1.00
Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One (2010) 0.98
Analysis of the ontogenetic variation in the venom proteome/peptidome of Bothrops jararaca reveals different strategies to deal with prey. J Proteome Res (2010) 0.94
Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes Infect (2008) 0.94
Expression of Streptococcus pneumoniae antigens, PsaA (pneumococcal surface antigen A) and PspA (pneumococcal surface protein A) by Lactobacillus casei. FEMS Microbiol Lett (2003) 0.94
Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun (2002) 0.94
Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine (2010) 0.93
Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol (2008) 0.93
Transcriptomic basis for an antiserum against Micrurus corallinus (coral snake) venom. BMC Genomics (2009) 0.92
Evaluation of the expression and protective potential of Leptospiral sphingomyelinases. Curr Microbiol (2009) 0.91
A prothrombin activator from Bothrops erythromelas (jararaca-da-seca) snake venom: characterization and molecular cloning. Biochem J (2003) 0.91
Snake venomics and venom gland transcriptomic analysis of Brazilian coral snakes, Micrurus altirostris and M. corallinus. J Proteomics (2011) 0.91
Some aspects of the venom proteome of the Colubridae snake Philodryas olfersii revealed from a Duvernoy's (venom) gland transcriptome. FEBS Lett (2006) 0.91
Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol (2009) 0.91
Economical value of vaccines for the developing countries--the case of Instituto Butantan, a public institution in Brazil. PLoS Negl Trop Dis (2011) 0.90
Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS One (2011) 0.90
SMase II, a new sphingomyelinase D from Loxosceles laeta venom gland: molecular cloning, expression, function and structural analysis. Toxicon (2009) 0.90
Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect Immun (2004) 0.89
Variations in Loxosceles spider venom composition and toxicity contribute to the severity of envenomation. Toxicon (2005) 0.89
Bothrops jararaca venom proteome rearrangement upon neonate to adult transition. Proteomics (2011) 0.89
Bothrops insularis venomics: a proteomic analysis supported by transcriptomic-generated sequence data. J Proteomics (2009) 0.89
Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil. J Clin Microbiol (2006) 0.89
Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains. Microb Pathog (2009) 0.88
Surfactant protein-A and phosphatidylglycerol suppress type IIA phospholipase A2 synthesis via nuclear factor-kappaB. Am J Respir Crit Care Med (2003) 0.88
Characterization of polysaccharide production of haemophilus influenzae Type b and its relationship to bacterial cell growth. Appl Biochem Biotechnol (2003) 0.87
Expressed sequence tags (ESTs) from the salivary glands of the tick Amblyomma cajennense (Acari: Ixodidae). Toxicon (2007) 0.87
Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast. Infect Immun (2013) 0.87
Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice. Infect Immun (2004) 0.87
Influenza vaccine production for Brazil: a classic example of successful North-South bilateral technology transfer. Vaccine (2011) 0.87
Venomics profiling of Thamnodynastes strigatus unveils matrix metalloproteinases and other novel proteins recruited to the toxin arsenal of rear-fanged snakes. J Proteome Res (2012) 0.86
Vero-cell rabies vaccine produced using serum-free medium. Vaccine (2004) 0.86
Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microb Pathog (2010) 0.86
Mycobacterial codon optimization of the gene encoding the Sm14 antigen of Schistosoma mansoni in recombinant Mycobacterium bovis Bacille Calmette-Guérin enhances protein expression but not protection against cercarial challenge in mice. FEMS Immunol Med Microbiol (2006) 0.85
Increased immunogenicity to LipL32 of Leptospira interrogans when expressed as a fusion protein with the cholera toxin B subunit. Curr Microbiol (2010) 0.85
DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein. J Med Microbiol (2006) 0.85
Haemagglutination induced by Bordetella pertussis filamentous haemagglutinin adhesin (FHA) is inhibited by antibodies produced against FHA(430-873) fragment expressed in Lactobacillus casei. Curr Microbiol (2006) 0.84
Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge. Microbes Infect (2007) 0.82
Acellular and "low" pertussis vaccines: adverse events and the role of mutations. Rev Inst Med Trop Sao Paulo (2009) 0.82
A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. Vaccine (2011) 0.81
Analysis of the subproteomes of proteinases and heparin-binding toxins of eight Bothrops venoms. Proteomics (2009) 0.81
Metabolic active-high density VERO cell cultures on microcarriers following apoptosis prevention by galactose/glutamine feeding. J Biotechnol (2002) 0.81
Optimizing expression of Streptococcus pneumoniae surface protein a, PspA: serocross-reactivity within families of antisera induced against clades 1 and 3. Mol Biotechnol (2007) 0.80
Immunization of mice with Lactobacillus casei expressing intimin fragments produces antibodies able to inhibit the adhesion of enteropathogenic Escherichia coli to cultivated epithelial cells. FEMS Immunol Med Microbiol (2008) 0.79
Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil. J Med Microbiol (2003) 0.79
DNA vaccines based on genetically detoxified derivatives of pneumolysin fail to protect mice against challenge with Streptococcus pneumoniae. FEMS Immunol Med Microbiol (2006) 0.79
Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C. Vaccine (2004) 0.78
Cross-reactivity of antipneumococcal surface protein C (PspC) antibodies with different strains and evaluation of inhibition of human complement factor H and secretory IgA binding via PspC. Clin Vaccine Immunol (2012) 0.78
Evaluation of the use of selective PCR amplification of LPS biosynthesis genes for molecular typing of leptospira at the serovar level. Curr Microbiol (2010) 0.78
Antibodies produced against a fragment of filamentous haemagglutinin (FHA) of Bordetella pertussis are able to inhibit hemagglutination induced by the whole adhesin. FEMS Microbiol Lett (2004) 0.78
An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum Vaccin Immunother (2013) 0.78